While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Estimate Revisions Trend The earnings report, which is expected to be released on August 6, 2024, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. This drug ...

Exelixis, Inc. (EXEL) entered into a settlement agreement with Cipla, which was looking to market a generic version of Cabometyx (cabozantinib). Cabometyx is Exelixis' lead drug. The settlement agreement resolves two patent litigations brought by Exelixis in response to Cipla's abbreviated new drug application (ANDA). The ANDA is seeking approval to market generic versions of Cabometyx tablets prior to the expiration of the applicable patents. The first case relates to Cipla's ANDA for a 60 mg cabozantinib ...

These stocks are both experts in their respective fields.Many billionaire investors are going all in on artificial intelligence (AI). That's understandable. AI is quickly being integrated into businesses' day-to-day operations. The leaders in the field could deliver outsized returns. However, there are other exciting investment opportunities out there. Consider Renaissance Technologies, a hedge fund headed by Jim Simons. The fund's holdings feature several healthcare stocks. That includes two notable drugma ...

Have you assessed how the international operations of Exelixis (EXEL) performed in the quarter ended March 2024? For this drug developer, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importan ...

Exelixis, Inc. (EXEL) reported lower-than-expected results for the first quarter. Its shares fell 7% in after-hours trading following the announcement.EXEL recorded earnings of 17 cents per share, which missed the Zacks Consensus Estimate of 28 cents. The company registered adjusted earnings of 16 cents per share in the first quarter of 2023.Including stock-based compensation expense, EPS was 12 cents, flat year over year.Net revenues were $425.2 million, which lagged the Zacks Consensus Estimate of $468 mi ...

Michael Morrissey Operator Jay Olson Amy Peterson Sure. Thanks for the question. I'll take that. This is Amy. So you saw in the slides, we do have a variety of cohorts that we are expanding in both STELLAR-001 and STELLAR-002 and in combination with PD-1 in addition to other IO agents, including CTLA-4 and LAG-3. We will present the data when it is mature. Some of these are early line cohorts. It just takes a while because you want to get ORR, you want to get DOR, you want to get PFS. Some of them actually ...

For the quarter ended March 2024, Exelixis (EXEL) reported revenue of $425.23 million, up 4% over the same period last year. EPS came in at $0.17, compared to $0.16 in the year-ago quarter.The reported revenue represents a surprise of -9.07% over the Zacks Consensus Estimate of $467.64 million. With the consensus EPS estimate being $0.28, the EPS surprise was -39.29%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their n ...

Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian@exelixis.com Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million - - Restructuring Expenses of $32.8 million Recorded - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.17 - - ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Regeneron (REGN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with p ...

Exelixis Inc. (EXEL, Financial) is a pharmaceutical company headquartered in Alameda, California that focuses on developing medicines to treat patients with various types of cancer. Investment thesis In recent years, the company's management has continued to delight investors with significant growth in its commercial business and expansion of its drug development pipeline, making Exelixis a leading player in the renal cell carcinoma market. The first investment thesis we highlight is the detailed results of ...